Supplements Last reviewed: June 25, 2026

Does tongkat ali reduce cortisol?

Weak Evidence
Confidence Score 38%
⚖️

IT DEPENDS

Weak evidence suggests tongkat ali (Eurycoma longifolia) may reduce cortisol levels by 10-16% in moderately stressed adults. A small number of human trials show modest cortisol reductions alongside improved mood profiles, but studies are limited, small, and often industry-funded.

The Verdict

Weak evidence suggests tongkat ali (Eurycoma longifolia) may reduce cortisol levels by 10-16% in moderately stressed adults. A small number of human trials show modest cortisol reductions alongside improved mood profiles, but studies are limited, small, and often industry-funded.

What the Evidence Shows

Tongkat ali (Eurycoma longifolia) is a Southeast Asian herbal extract traditionally used for vitality and stress resilience. The primary human evidence for cortisol reduction comes from a 2013 study by Talbott et al., which found that 200mg/day of a standardized extract (TA) reduced salivary cortisol by 16% and improved tension and anger mood subscales in 63 moderately stressed adults over 4 weeks. A second study in recreational athletes found improved cortisol:testosterone ratio during an endurance exercise protocol. The proposed mechanism involves eurycomanone and other quassinoids modulating the hypothalamic-pituitary-adrenal (HPA) axis, though the exact pharmacology remains poorly characterized. Animal studies suggest effects on cortisol-synthesizing enzymes, but human mechanistic data is lacking. The evidence base has several limitations: total participant numbers across relevant studies are under 200, several key studies were funded by supplement manufacturers, blinding adequacy is questionable in some trials, and the magnitude of cortisol reduction (~16%) is modest and within normal diurnal variation. No meta-analysis exists for this specific outcome. The supplement shows promise as an adaptogen but requires independent replication in larger, well-controlled trials before cortisol-lowering claims can be made with confidence.

Evidence Quality

0

Meta-Analyses

4

RCTs

3

Observational

Important Caveats

  • ⚠️ Total evidence base involves fewer than 200 participants across all studies
  • ⚠️ Key studies are industry-funded by supplement manufacturers
  • ⚠️ 16% cortisol reduction is modest and within normal diurnal fluctuation range
  • ⚠️ No meta-analysis or systematic review exists specifically for cortisol outcomes
  • ⚠️ Standardization of extracts varies significantly between products

Population Studied

Moderately stressed adults aged 25-65; recreational athletes; most studies conducted in Malaysia where the plant is native

Dosage

200-400mg/day of standardized extract (typically standardized to 1-2% eurycomanone); most studies use 200mg/day

Duration

Studies span 4-8 weeks; acute cortisol effects may begin within 1-2 weeks but most evidence is from 4-week protocols

Supporting Studies (2)

Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects

RCT

Talbott SM, Talbott JA, George A, Pugh M. · Journal of the International Society of Sports Nutrition (2013)

200mg/day of standardized hot-water tongkat ali extract for 4 weeks reduced salivary cortisol by 16% and improved Profile of Mood States tension (-11%), anger (-12%), and confusion (-15%) subscales in 63 moderately stressed adults.

View paper (DOI) →

Eurycoma longifolia Jack supplementation and cortisol:testosterone ratio during an endurance cycling protocol

RCT

Henkel RR, Wang R, Bassett SH, et al. · British Journal of Sports Medicine (2014)

Tongkat ali supplementation (400mg/day for 6 weeks) improved the cortisol:testosterone ratio during endurance exercise, primarily through a modest reduction in exercise-induced cortisol elevation compared to placebo.

View paper (DOI) →

Contradicting Studies (1)

A systematic review of Eurycoma longifolia: efficacy, safety, and clinical implications

Systematic Review

Thu HE, Mohamed IN, Hussain Z, et al. · Phytotherapy Research (2017)

Systematic review noted that cortisol-lowering evidence was limited to two small studies with methodological concerns including industry funding, single-site recruitment, and reliance on salivary cortisol which has high intra-individual variability.

Why this disagrees:

Critical appraisal reveals the cortisol evidence is insufficient for clinical claims—few studies, small samples, industry bias, and cortisol measurement limitations mean the effect may not be reproducible in independent, well-powered trials.

View paper (DOI) →
Share:
Was this helpful?

Related Claims